We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Complete Genomics Partners with Inova Health System to Sequence the Genomes of 500 Infants and Their Parents

By LabMedica International staff writers
Posted on 22 Sep 2011
Complete Genomics, Inc. More...
(Mountain View, CA, USA), a human genome sequencing company, and Inova Health System (Falls Church, VA, USA), a not-for-profit healthcare system, announced additional details about their partnership to sequence 1,500 genomes from 500 infants and their parents. The goal of this project is to identify prognostic, diagnostic, and therapeutic targets for pre-term delivery and potentially other obstetrics-associated abnormalities.

This project was first announced during Complete Genomics’ Q2 earnings call on August 4, 2011. This partnership is part of a pilot program with the Inova Translational Medicine Institute (ITMI), a not-for-profit research institute within the Inova Health System geared at translating clinical research into actual care programs using genomically driven patient care, frequently referred to as personalized medicine.

“Complete Genomics is a natural choice as our sequencing partner for this new program,” said John Niederhuber, CEO, Inova Translational Medicine Institute. “We are confident that Complete Genomics can manage a large project of this type efficiently and produce the consistent, high-quality sequencing data that we need to be able to understand the subtle genetic changes that contribute to pre-term delivery.”

“The Inova Translational Medicine Institute is truly an innovator in the delivery of patient care, striving to not only understand the genomic makeup of patients, but also to customize care to the individual to help prevent or manage their diseases,” said Dr. Clifford Reid, chairman, president and CEO of Complete Genomics. “We view this as an important opportunity for our sequencing service to potentially help create new treatment options for some of the smallest and sickest patients in the hospital.”

ITMI has already begun collecting DNA samples for Complete Genomics to begin sequencing in September. Complete Genomics will begin delivering variant reports to ITMI as early as Q4 and expects to complete most of the 1,500 genomes in the first quarter of 2012. These results will detail how the genomes of pre-term delivery babies from Inova Fairfax Hospital’s Joint Commission-certified neonatal intensive care unit (NICU) compare with reference genomes. They will include data about the single nucleotide polymorphisms (SNPs), insertions/deletions, copy number variations, and structural variations included in each DNA sample, together with the read alignments supporting those calls, coverage information and quality scores. In addition to sequence-based data, ITMI will also generate epigenomic, expression, and micro-RNA data on each sample. Data from Inova Health System's electronic medical record system will support ITMI’s outcomes-based research.

Complete Genomics is a human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA Platform) combines Complete Genomics’ proprietary human genome sequencing technology with advanced informatics and data management software. This solution is offered as an, outsourced service, CGA Service, and provides customers with data that is immediately ready to be used for genome-based research.

Related Links:
Complete Genomics
Inova Health System
Inova Translational Medicine Institute



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.